Skip to main content
71°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about treatment/resistant depression
Recent news which mentions treatment/resistant depression
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
Tags
Psychedelics
Benzinga
Florian Brand
From
Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
Tickers
JNJ
NEWS
Tags
eketamine nasal spray
Cannabis
treatment/resistant depression
From
Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
April 26, 2024
Tickers
NEWS
Tags
treatment/resistant depression
Beckley Psytech Ltd
Rob Conley
From
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
March 28, 2024
Tickers
ATAI
NEWS
Tags
News
5/MeO/DMT
treatment/resistant depression
From
Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
Tags
treatment/resistant depression
Management
Psychedelic/Assisted Therapies
From
Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
Tickers
AWKNF
CMPS
Tags
Penny Stocks
Legal
AWKNF
From
Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
October 03, 2023
Tickers
ATAI
Tags
News
DMT Clinical Trial
Penny Stocks
From
Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
Tags
Psychedelics
Benzinga
CMPS
From
Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
August 24, 2023
Tickers
GHRS
Tags
Cannabis
treatment/resistant depression
Psychedelic/Assisted Therapies
From
Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
Tags
News
Markets
Psychedelics
From
Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
July 05, 2023
Tickers
ATAI
CMPS
HTGC
Tags
treatment/resistant depression
Psychedelic/Assisted Therapies
Small Cap
From
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
May 30, 2023
Tickers
CMPS
NUMIF
Tags
News
Markets
Market News
From
Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
May 11, 2023
Tickers
GHRS
Tags
General
Markets
GHRS
From
Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
May 04, 2023
Tags
Markets
General
5/MeO/DMT
From
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
Tickers
ATAI
CMPS
IGXT
Tags
Cannabis
treatment/resistant depression
Ark Fund
From
Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
Tags
Markets
News
Cannabis
From
Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
Tags
Compass Pathways
Markets
Legal
From
Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
November 16, 2022
Tickers
CMPS
Tags
treatment/resistant depression
Psychedelic/Assisted Therapies
Small Cap
From
Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
November 02, 2022
Tags
Financing
5/MeO/DMT
News
From
Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
October 05, 2022
Tickers
ATAI
Tags
News
DMT Clinical Trial
ATAI Life Sciences
From
Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
July 28, 2022
Tickers
CMPS
Tags
Small Cap
treatment/resistant depression
Columbia University Irving Medical School
From
Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
April 12, 2022
Tags
Markets
Cannabis
treatment/resistant depression
From
Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
Tags
Cannabis
Positive and Negative Affect Schedule
Small Cap
From
Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
November 16, 2021
Tickers
GHRS
Tags
treatment/resistant depression
Topics
Cannabis
From
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.